Response to Lex Wunderink's query as to whether the development of supersensitivity could explain the greater risk of relapse in individuals with a longer duration of treatment with antipsychotic medication.
Identifieur interne : 000C95 ( Main/Exploration ); précédent : 000C94; suivant : 000C96Response to Lex Wunderink's query as to whether the development of supersensitivity could explain the greater risk of relapse in individuals with a longer duration of treatment with antipsychotic medication.
Auteurs : Meghan Bowtell [Australie] ; Aswin Ratheesh [Australie] ; Brian O'Donoghue [Australie]Source :
- Schizophrenia research [ 1573-2509 ] ; 2018.
Descripteurs français
- KwdFr :
- MESH :
English descriptors
- KwdEn :
- MESH :
- chemical : Antipsychotic Agents.
- Duration of Therapy, Humans, Psychotic Disorders, Recurrence.
DOI: 10.1016/j.schres.2018.02.006
PubMed: 29459051
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Response to Lex Wunderink's query as to whether the development of supersensitivity could explain the greater risk of relapse in individuals with a longer duration of treatment with antipsychotic medication.</title><author><name sortKey="Bowtell, Meghan" sort="Bowtell, Meghan" uniqKey="Bowtell M" first="Meghan" last="Bowtell">Meghan Bowtell</name><affiliation wicri:level="4"><nlm:affiliation>Orygen, The National Centre of Excellence in Youth Mental Health, Melbourne, Australia; Centre for Youth Mental Health, University of Melbourne.</nlm:affiliation><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName><orgName type="university">Université de Melbourne</orgName></affiliation></author><author><name sortKey="Ratheesh, Aswin" sort="Ratheesh, Aswin" uniqKey="Ratheesh A" first="Aswin" last="Ratheesh">Aswin Ratheesh</name><affiliation wicri:level="1"><nlm:affiliation>Orygen, The National Centre of Excellence in Youth Mental Health, Melbourne, Australia; Centre for Youth Mental Health, University of Melbourne; Orygen Youth Health, 35 Poplar rd, Parkville, VIC, Australia. Electronic address: aswin.ratheesh@orygen.org.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Orygen, The National Centre of Excellence in Youth Mental Health, Melbourne, Australia; Centre for Youth Mental Health, University of Melbourne; Orygen Youth Health, 35 Poplar rd, Parkville, VIC</wicri:regionArea><wicri:noRegion>VIC</wicri:noRegion></affiliation></author><author><name sortKey="O Donoghue, Brian" sort="O Donoghue, Brian" uniqKey="O Donoghue B" first="Brian" last="O'Donoghue">Brian O'Donoghue</name><affiliation wicri:level="1"><nlm:affiliation>Orygen, The National Centre of Excellence in Youth Mental Health, Melbourne, Australia; Centre for Youth Mental Health, University of Melbourne; Orygen Youth Health, 35 Poplar rd, Parkville, VIC, Australia. Electronic address: brian.odonoghue@orygen.org.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Orygen, The National Centre of Excellence in Youth Mental Health, Melbourne, Australia; Centre for Youth Mental Health, University of Melbourne; Orygen Youth Health, 35 Poplar rd, Parkville, VIC</wicri:regionArea><wicri:noRegion>VIC</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:29459051</idno><idno type="pmid">29459051</idno><idno type="doi">10.1016/j.schres.2018.02.006</idno><idno type="wicri:Area/Main/Corpus">000F58</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000F58</idno><idno type="wicri:Area/Main/Curation">000F58</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000F58</idno><idno type="wicri:Area/Main/Exploration">000F58</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Response to Lex Wunderink's query as to whether the development of supersensitivity could explain the greater risk of relapse in individuals with a longer duration of treatment with antipsychotic medication.</title><author><name sortKey="Bowtell, Meghan" sort="Bowtell, Meghan" uniqKey="Bowtell M" first="Meghan" last="Bowtell">Meghan Bowtell</name><affiliation wicri:level="4"><nlm:affiliation>Orygen, The National Centre of Excellence in Youth Mental Health, Melbourne, Australia; Centre for Youth Mental Health, University of Melbourne.</nlm:affiliation><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName><orgName type="university">Université de Melbourne</orgName></affiliation></author><author><name sortKey="Ratheesh, Aswin" sort="Ratheesh, Aswin" uniqKey="Ratheesh A" first="Aswin" last="Ratheesh">Aswin Ratheesh</name><affiliation wicri:level="1"><nlm:affiliation>Orygen, The National Centre of Excellence in Youth Mental Health, Melbourne, Australia; Centre for Youth Mental Health, University of Melbourne; Orygen Youth Health, 35 Poplar rd, Parkville, VIC, Australia. Electronic address: aswin.ratheesh@orygen.org.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Orygen, The National Centre of Excellence in Youth Mental Health, Melbourne, Australia; Centre for Youth Mental Health, University of Melbourne; Orygen Youth Health, 35 Poplar rd, Parkville, VIC</wicri:regionArea><wicri:noRegion>VIC</wicri:noRegion></affiliation></author><author><name sortKey="O Donoghue, Brian" sort="O Donoghue, Brian" uniqKey="O Donoghue B" first="Brian" last="O'Donoghue">Brian O'Donoghue</name><affiliation wicri:level="1"><nlm:affiliation>Orygen, The National Centre of Excellence in Youth Mental Health, Melbourne, Australia; Centre for Youth Mental Health, University of Melbourne; Orygen Youth Health, 35 Poplar rd, Parkville, VIC, Australia. Electronic address: brian.odonoghue@orygen.org.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Orygen, The National Centre of Excellence in Youth Mental Health, Melbourne, Australia; Centre for Youth Mental Health, University of Melbourne; Orygen Youth Health, 35 Poplar rd, Parkville, VIC</wicri:regionArea><wicri:noRegion>VIC</wicri:noRegion></affiliation></author></analytic><series><title level="j">Schizophrenia research</title><idno type="eISSN">1573-2509</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antipsychotic Agents (MeSH)</term><term>Duration of Therapy (MeSH)</term><term>Humans (MeSH)</term><term>Psychotic Disorders (MeSH)</term><term>Recurrence (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Humains (MeSH)</term><term>Neuroleptiques (MeSH)</term><term>Récidive (MeSH)</term><term>Troubles psychotiques (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Antipsychotic Agents</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Duration of Therapy</term><term>Humans</term><term>Psychotic Disorders</term><term>Recurrence</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Neuroleptiques</term><term>Récidive</term><term>Troubles psychotiques</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">29459051</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>26</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2509</ISSN><JournalIssue CitedMedium="Internet"><Volume>197</Volume><PubDate><Year>2018</Year><Month>07</Month></PubDate></JournalIssue><Title>Schizophrenia research</Title><ISOAbbreviation>Schizophr Res</ISOAbbreviation></Journal><ArticleTitle>Response to Lex Wunderink's query as to whether the development of supersensitivity could explain the greater risk of relapse in individuals with a longer duration of treatment with antipsychotic medication.</ArticleTitle><Pagination><MedlinePgn>599-600</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0920-9964(18)30055-0</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.schres.2018.02.006</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bowtell</LastName><ForeName>Meghan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Orygen, The National Centre of Excellence in Youth Mental Health, Melbourne, Australia; Centre for Youth Mental Health, University of Melbourne.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratheesh</LastName><ForeName>Aswin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Orygen, The National Centre of Excellence in Youth Mental Health, Melbourne, Australia; Centre for Youth Mental Health, University of Melbourne; Orygen Youth Health, 35 Poplar rd, Parkville, VIC, Australia. Electronic address: aswin.ratheesh@orygen.org.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Donoghue</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Orygen, The National Centre of Excellence in Youth Mental Health, Melbourne, Australia; Centre for Youth Mental Health, University of Melbourne; Orygen Youth Health, 35 Poplar rd, Parkville, VIC, Australia. Electronic address: brian.odonoghue@orygen.org.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>02</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Schizophr Res</MedlineTA><NlmUniqueID>8804207</NlmUniqueID><ISSNLinking>0920-9964</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Schizophr Res. 2018 Jul;197:65-66</RefSource><PMID Version="1">29128323</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="Y">Antipsychotic Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000081206" MajorTopicYN="N">Duration of Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="Y">Psychotic Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>02</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>02</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29459051</ArticleId><ArticleId IdType="pii">S0920-9964(18)30055-0</ArticleId><ArticleId IdType="doi">10.1016/j.schres.2018.02.006</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li></country><region><li>Victoria (État)</li></region><settlement><li>Melbourne</li></settlement><orgName><li>Université de Melbourne</li></orgName></list><tree><country name="Australie"><region name="Victoria (État)"><name sortKey="Bowtell, Meghan" sort="Bowtell, Meghan" uniqKey="Bowtell M" first="Meghan" last="Bowtell">Meghan Bowtell</name></region><name sortKey="O Donoghue, Brian" sort="O Donoghue, Brian" uniqKey="O Donoghue B" first="Brian" last="O'Donoghue">Brian O'Donoghue</name><name sortKey="Ratheesh, Aswin" sort="Ratheesh, Aswin" uniqKey="Ratheesh A" first="Aswin" last="Ratheesh">Aswin Ratheesh</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C95 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C95 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PoplarV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:29459051
|texte= Response to Lex Wunderink's query as to whether the development of supersensitivity could explain the greater risk of relapse in individuals with a longer duration of treatment with antipsychotic medication.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:29459051" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PoplarV1
| This area was generated with Dilib version V0.6.37. |  |